Search research articles
Contact Us
Filters
Showing results (221-230 of 226) with videos related to
Page
of 23
Sort By:
You have reached the last page of results.
This site can display upto 226 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2021
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]
K L Jhaveri, X V Wang, V Makker, et al.
Nature Communications
|
January 25, 2023
Author Correction: A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA
Anna-Lisa Doebley, Minjeong Ko, Hanna Liao, et al.
Nature Communications
|
December 3, 2022
A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA
Anna-Lisa Doebley, Minjeong Ko, Hanna Liao, et al.
Biorxiv : the Preprint Server for Biology
|
February 23, 2026
Deep learning-based non-invasive profiling of tumor transcriptomes from cell-free DNA for precision oncology
Robert D Patton, Alexander Netzley, Thomas W Persse, et al.
NPJ Precision Oncology
|
March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
A S Mansfield, Z Wei, R Mehra, et al.
Cancer Discovery
|
November 18, 2022
Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Navonil De Sarkar, Robert D Patton, Anna-Lisa Doebley, et al.
Page
of 23
Search research articles
Search
Showing results (221-230 of 226) with videos related to
Sort By:
Page
of 23
You have reached the last page of results.
This site can display upto 226 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2021
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]
K L Jhaveri, X V Wang, V Makker, et al.
Nature Communications
|
January 25, 2023
Author Correction: A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA
Anna-Lisa Doebley, Minjeong Ko, Hanna Liao, et al.
Nature Communications
|
December 3, 2022
A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA
Anna-Lisa Doebley, Minjeong Ko, Hanna Liao, et al.
Biorxiv : the Preprint Server for Biology
|
February 23, 2026
Deep learning-based non-invasive profiling of tumor transcriptomes from cell-free DNA for precision oncology
Robert D Patton, Alexander Netzley, Thomas W Persse, et al.
NPJ Precision Oncology
|
March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
A S Mansfield, Z Wei, R Mehra, et al.
Cancer Discovery
|
November 18, 2022
Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Navonil De Sarkar, Robert D Patton, Anna-Lisa Doebley, et al.
Page
of 23